➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 9,540,410

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,540,410
Title:Gemcitabine prodrugs and uses thereof
Abstract: The present invention provides compounds according to formula I: ##STR00001## and pharmaceutically acceptable salts thereof. For compounds of formula I, R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2-aryl, and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH-aryl. The subscript n is from 2 to 6. R.sup.3 is selected from the group consisting of H and --C(.dbd.O)--O--R.sup.4; and R.sup.4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R.sup.1 and R.sup.2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided.
Inventor(s): Wu; Laurence I. (Taipei, TW)
Application Number:14/599,166
Patent Claims:see list of patent claims

Details for Patent 9,540,410

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial BOYEN THERAPEUTICS, INC. (Taipei, TW) 2032-11-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.